Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
Open Access
- 30 July 2013
- journal article
- Published by Springer Science and Business Media LLC in Clinical Epigenetics
- Vol. 5 (1), 12
- https://doi.org/10.1186/1868-7083-5-12
Abstract
No abstract availableKeywords
This publication has 128 references indexed in Scilit:
- Inhibition of Mammalian Target of Rapamycin in Human Acute Myeloid Leukemia Cells Has Diverse Effects That Depend on the Environmental In Vitro StressBone Marrow Research, 2012
- Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategiesClinical Epigenetics, 2011
- Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemiaBlood Cancer Journal, 2011
- Molecular marks for epigenetic identification of developmental and cancer stem cellsClinical Epigenetics, 2010
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapyClinical Epigenetics, 2010
- Histone deacetylase inhibitors: clinical implications for hematological malignanciesClinical Epigenetics, 2010
- Combination of Intensive Chemotherapy and Anticancer Vaccines in the Treatment of Human Malignancies: The Hematological ExperienceJournal of Biomedicine and Biotechnology, 2010
- Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cellsCell Stress and Chaperones, 2008
- The Epigenomics of CancerCell, 2007
- Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood, 2006